Control Allergic Itch & Earn Up To $80 in Rewards
Join our free pet health Rewards program. Spend your Rewards on products and services at the vet!
Prescribed for Over 15 Million Dogs and Counting2
Apoquel stops allergic itch right at the source.3
All dogs itch sometimes, but when you notice it happening more and more, it could be a sign of a medical condition.
- The #1 prescribed oral medication for allergic itch in dogs.1
- Available as a pork-liver flavored chewable for even easier daily dosing.
- Can be used for long-term maintenance or short-term therapy in dogs 12 months of age and older.4,5
IMPORTANT SAFETY INFORMATION: See full Apoquel Tablet and Apoquel Chewable Prescribing Information. Do not use Apoquel or Apoquel Chewable in dogs less than 12 months of age or those with serious infections. Apoquel and Apoquel Chewable may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre- existing cancers to get worse. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. New neoplastic conditions (benign and malignant) were observed in clinical studies and post- approval. Apoquel and Apoquel Chewable have not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporines. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. Apoquel and Apoquel Chewable have been used safely with many common medications including parasiticides, antibiotics and vaccines.
INDICATIONS: Control of pruritus (itching) associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
*Vets, n=250; pet owners, n=491.
References:
- Kynetec - PetTrak, US Pruritus Factored National. MAT Canine Pruritus, Total Unique Patients on Apoquel. Dec. 2023, Zoetis Inc.
- Kynetec PetTrak – GAH-284: Unique Patient Count Since Launch Custom Report: Apoquel: January 2014 – February 2024.
- Gonzales AJ, Bowman JW, Fici GJ, et al. Oclacitinib (APOQUEL(®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. Journal of Veterinary Pharmacology and Therapeutics. 2014;37(4):317-324. doi:10.1111/vp.12101.
- Cosgrove SB, Wren JA, Cleaver DM, et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol. 2013;24(5):479- e114. doi: 10.1111/vde.12047.
- Cosgrove SB, Cleaver DM, King VL, et al. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. Vet Dermatol. 2015;26(3):171-179, e35. doi: 10.1111/vde.12194.
APQ-00679R12
